---
title: "Rituximab - Non-Hodgkin'S Lymphoma"
sidebar: mydoc_sidebar
permalink: db00240-mesh-d008228-1.html
toc: false 
---


Path ID: `DB00240_MESH_D008228_1`
{% include image.html url="images/db00240-mesh-d008228-1.png" file="db00240-mesh-d008228-1.png" alt="db00240-mesh-d008228-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:D000069283 | rituximab | Drug |
| UniProt:P11836 | B-lymphocyte antigen CD20 | Protein |
| GO:0006959 | humoral immune response | BiologicalProcess |
| GO:0001788 | antibody-dependent cellular cytotoxicity | BiologicalProcess |
| GO:0097278 | complement-dependent cytotoxicity | BiologicalProcess |
| MESH:D008228 | Non-Hodgkin's lymphoma | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Rituximab | MOLECULARLY INTERACTS WITH | B-Lymphocyte Antigen Cd20 |
| B-Lymphocyte Antigen Cd20 | REGULATES | Humoral Immune Response |
| Humoral Immune Response | CORRELATED WITH | Antibody-Dependent Cellular Cytotoxicity |
| Humoral Immune Response | CORRELATED WITH | Complement-Dependent Cytotoxicity |
| Antibody-Dependent Cellular Cytotoxicity | NEGATIVELY CORRELATED WITH | Non-Hodgkin'S Lymphoma |
| Complement-Dependent Cytotoxicity | NEGATIVELY CORRELATED WITH | Non-Hodgkin'S Lymphoma |
|---------|-----------|---------|

Reference: 
  - [https://go.drugbank.com/drugs/DB00073](https://go.drugbank.com/drugs/DB00073)
  - [https://en.wikipedia.org/wiki/Rituximab#Mechanisms_of_action](https://en.wikipedia.org/wiki/Rituximab#Mechanisms_of_action)
  - [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rituximab?redirect=true](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/rituximab?redirect=true)
